Acute visual loss after ipilimumab treatment for metastatic melanoma

BACKGROUND: Ipilimumab, a humanized CLTA-4 antibody is a standard therapy in the treatment of advanced melanoma. While ipilimumab provides an overall survival benefit to patients, it can be associated with immune related adverse events (IrAEs). CASE PRESENTATION: Here we describe a patient treated w...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Immunother Cancer
Autores principales: Wilson, Melissa A., Guld, Kelly, Galetta, Steven, Walsh, Ryan D., Kharlip, Julia, Tamhankar, Madhura, McGettigan, Suzanne, Schuchter, Lynn M., Fecher, Leslie A.
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2016
Materias:
Case Report
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5067900/
https://ncbi.nlm.nih.gov/pubmed/27777775
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-016-0170-9
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares